Methotrexate: A detailed review on drug delivery and clinical aspects

Expert Opinion on Drug Delivery

Volumn 9, Issue 2, 2012, Pages 151-169

  Khan, Zulfequar Ahamad ^a   Tripathi, Rahul ^a   Mishra, Brahmeshwar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

abortion; cancer; liposomes; methotrexate; misoprostol; nanoparticles; prodrug and drug conjugates; rheumatoid arthritis

Indexed keywords

AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CARBAPENEM DERIVATIVE; CEFOPERAZONE; CELECOXIB; CISPLATIN; COTRIMOXAZOLE; DEXAMETHASONE; DIGOXIN; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; MISOPROSTOL; NANOPARTICLE; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; NYSTATIN; PENICILLIN DERIVATIVE; PHENYLBUTAZONE; PHENYTOIN; POLYMYXIN B; PROBENECID; PURINE DERIVATIVE; PYRIMIDINE; SALICYLIC ACID DERIVATIVE; SULFAMETHOXAZOLE; SULFONAMIDE; TRANQUILIZER; UNINDEXED DRUG; VANCOMYCIN;

ABORTION; ACUTE LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIPROTOZOAL ACTIVITY; AREA UNDER THE CURVE; BONE MARROW DEPRESSION; CHILDHOOD LEUKEMIA; CHORIOCARCINOMA; COLORECTAL CANCER; CONTROLLED DRUG RELEASE; DERMATITIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MONITORING; DRUG OVERDOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SOLUBILITY; ECCHYMOSIS; HEAD AND NECK CANCER; HEPATITIS; HUMAN; LUNG FIBROSIS; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; OSTEOARTHRITIS; PARTICLE SIZE; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; TRANSITIONAL CELL CARCINOMA; TROPHOBLASTIC TUMOR; UNSPECIFIED SIDE EFFECT; VOMITING;

ABORTION, INDUCED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIPARASITIC AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIPOSOMES; METHOTREXATE; MISOPROSTOL; NANOPARTICLES; PREGNANCY; PRODRUGS;

EID: 84856082845     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.642362     Document Type: Review

References (127)

1. Meyer LM, Miller FR, Rowen MJ, et al. Treatment of Acute Leukemia with Amethopterin (4-amino, 10-methyl pteroyl glutamic acid). Acta Haematol 1950;9:157-67
2. Cronstein BN, Bertino JR. 2000. "Methotrexate: historical aspects". Methotrexate. Basel: Birkhauser. ISBN 978-3-7643-5959-1. . [Last accessed on 30 August 2011]
3. Available from: http://arthritis.about. com/od/mtx/p/methotrexate.htm [Last accessed on 01 May 2011]
4. Marven PA. FDA approves remicade (infliximab)/methotrexate combination to improve physical function in rheumatoid arthritis. Doctor's Guide. 2002. Available from: http://www.docguide.com/news/ content.nsf/news/ 8525697700573E1885256B6E00574353 [Last accessed on 02 May 2011]
5. Kasim NA, Whitehouse M, Ramachandran C, et al. Molecular properties of WHO essential drugs and provisional Biopharmaceutical Classification. Mol Pharm 2003;1:85-96
6. Fortea TC, Casabo VG, Nacher A, et al. Evidence of competitive inhibition of methotrexate absorption by leucovorin calcium in rat small intestine. Int J Pharm 1997;155:109-19 (Pubitemid 27368128)
7. Bremnes RM, Slordal L, Wist E, et al. Dose-dependent pharmacokinetics of methotrexate and 7-hydroxy methotrexate in the rat in vivo. Cancer Res 1989;49:6359-64 (Pubitemid 20000937)
8. Teresi ME, Crom WR, Choi KE, et al. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 1987;110:788-92 (Pubitemid 17074754)
9. Regenthal R, Krueger M, Koeppel C, et al. Drug levels: Therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit 1999;15:529-44 (Pubitemid 30311655)
10. Seidel H, Andersen A, Kvaloy JT, et al. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables. Leuk Res 2000;24:193-9 (Pubitemid 30083941)
11. Said S, Jeffes EWB, Weinstein GD. Systemic treatment: methotrexate. Clin Dermatol 1997;15:781-97
12. Stanley L, Marks P, Vulliet R, et al. Dietary composition alters methotrexate toxicity without changing its pharmacokinetic parameters in cats. Nutr Biochem 1997;8:79-84
13. Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology 2000;47:247-57 (Pubitemid 30394541)
14. Savion S, Shtelman E, Orenstein H, et al. Bax-associated mechanisms underlying the response of embryonic cells to methotrexate. Toxicol in Vitro 2009;23:1062-8
15. Moisa A, Fritz P, Benz D, et al. Iatrogenically-related, fatal methotrexate intoxication: a series of four cases. Forensic Sci Int 2006;156:154-7 (Pubitemid 43061258)
16. Chianga HM, Fang SH, Wen KC, et al. Life-threatening interaction between the root extract of Pueraria lobata and methotrexate in rats. Toxicol Appl Pharmacol 2005;209:263-8
17. Giverhaug T, Loennechen T, Aarbakke J. The interaction of 6-mercaptopurine (6-MP) and methotrexate. Gen Pharmacol 1999;33:341-6
18. Methotrexate. CCO Formulary Revised 2006/2007. Available from: http://www. cancercare.on.ca/pdfdrugs [Last accessed on 22 December 2010]
19. Fuksa L, Brcakova E, Kolouchova G, et al. Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats. Toxicology 2010;267:165-71
20. Bonetti A, Chatelut E, Kim S. An extended-release formulation of methotrexate for subcutaneous administration. Cancer Chemother Pharmacol 1994;33:303-6 (Pubitemid 24033054)
21. Chatelut E, Suh P, Kim S. Sustained-release methotrexate for intracavitary chemotherapy. J Pharm Sci 1994;83:429-32 (Pubitemid 24224225)
22. Chatelut E, Kim T, Kim S. A slow-release methotrexate formulation for intrathecal chemotherapy. Cancer Chemother Pharmacol 1993;32:179-82 (Pubitemid 23146809)
23. Singh UV. Udupa N. methotrexate loaded chitosan and chitin microspheres-in vitro characterization and pharmacokinetics in mice bearing Ehrlich ascites carcinoma. J Microencapsul 1998;15:581-94 (Pubitemid 28423169)
24. Karasulu HY, Karabulut B, Goker E, et al. Controlled release of methotrexate from w/o microemulsion and its in vitro antitumor activity. Drug Deliv 2007;14:225-33 (Pubitemid 46759432)
25. Lebugle A, Rodrigues A, Bonnevialle P, et al. Study of implantable calcium phosphate systems for the slow release of methotrexate. Biomaterials 2002;23:3517-22 (Pubitemid 34615660)
26. Wang F, Jiang X, Lu W. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm 2003;263:1-7 (Pubitemid 37087927)
27. Stewart GE II, Diaz JD, Lockey RF, et al. Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid- dependent asthma. J Allergy Clin Immunol 1994;94:482-9
28. Doddoli C, Ghez O, Baresi F, et al. In vitro and in vivo methotrexate disposition in alveolar macrophages: comparison of pharmacokinetic parameters of two formulations. Int J Pharm 2005;297:180-9 (Pubitemid 40720278)
29. Li Y, Vijayanathan V, Gulinello M, et al. Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine. Pharmacol Biochem Behav 2010;95:428-33
30. Choudhury RC, Ghosh SK, Palo AK. Cytogenetic toxicity of methotrexate in mouse bone marrow. Environ Toxicol Pharmacol 2000;8:191-6 (Pubitemid 30488182)
31. Narayani R, Rao KP. Biodegradable conjugates microspheres using two different gelatin drug for the controlled delivery of methotrexate. Int J Pharm 1996;128:261-8 (Pubitemid 26092161)
32. Devineni D, Blanton CD, Gallo JM. Preparation and in vitro evaluation of magnetic microsphere- methotrexateconjugate drug delivery systems. Bioconjug Chem 1995;6:203-10
33. Singh UV, Udupa N. In vitro characterization of methotrexate loaded poly(lactic-co-glycolic) acid microspheres and antitumor efficacy in Sarcoma-180 mice bearing tumor. Pharm Acta Helv 1997;72:165-73 (Pubitemid 27246715)
34. Narayani R, Rao KP. Solid tumor chemotherapy using injectable gelatin microspheres containing free methotrexate and conjugated methotrexate. Int J Pharm 1996;142:25-32 (Pubitemid 26343827)
35. Lee KC, Lee YJ, Kim WB, et al. Monoclonal antibody-based targeting of methotrexate -loaded microspheres Int J Pharm 1990;59:27-33 (Pubitemid 20143169)
36. Kim CK, Hwang SJ, Lee MG. The organ targetability of small and large albumin microspheres containing free and HSA conjugated methotrexate. Int J Pharm 1993;89:91-02
37. Comiskey SJ, Heath TD. Leakage and delivery of liposome-encapsulated methotrexate -gamma-aspartate in a chemically defined medium. Biochim Biophys Acta Biomembr 1990;1024:307-17 (Pubitemid 20182816)
38. Heath TD, Lopez NG, Papahadjopoulos D. The effects of liposome size and surface charge on liposome-mediated delivery of methotrexate -gamma-aspartate to cells in vitro. Biochim Biophys Acta Biomembr 1985;820:74-84 (Pubitemid 16233425)
39. Kotsifaki H, Kapoulas V, Deliconstantinos G. Targeting of liposomes containing methotrexate towards Tetrahymena pyriformis cells. Gen Pharmacother Vasc Syst 1985;16:573-7 (Pubitemid 16230753)
40. Needham D, Dewhirst MW. The development and testing of a new temperature - sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001;53:285-05
41. Zhua L, Huoa Z, Wanga L, et al. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int J Pharm 2009;370:136-43
42. Jones MN, Hudson MJH. The targeting of immunoliposomes to tumour cells (A431) and the effects of encapsulated methotrexate. Biochim Biophys Acta Biomembr 1993;1152:231-42 (Pubitemid 23330480)
43. Kim CK, Choi YJ, Jeong L S, et al. Lymph node targeting and pharmacokinetics of [3H] methotrexate encapsulated neutral large unilamellar vesicles and immunoliposomes. Int J Pharm 1993;98:9-18 (Pubitemid 23242385)
44. Boggs JM., Goundalkar A, Doganoglu F, et al. Antigen-targeted liposome-encapsulated methotrexate specifically kills lymphocytes sensitized to the nonapeptide of myelin basic protein. J Neuroimmunol 1987;17:35-48
45. Noe C, Borrell JH, Kinsky SC, et al. Inhibition of cell proliferation with antibody-targeted liposomes containing methotrexate -gamma-dimyristoyl phosphatidyl ethanolamine. Biochim Biophys Acta Biomembr 1988;946:253-60 (Pubitemid 19011352)
46. Singh M, Ghose T, Mezei M, et al. Inhibition of human renal cancer by monoclonal antibody targeted methotrexate -containing liposomes in an ascites tumor model. Cancer Lett 1991;56:97-02
47. Trotta M, Peira E, Carlotti ME, et al. Deformable liposomes for dermal administration of methotrexate. Int J Pharm 2004;270:119-25 (Pubitemid 38077093)
48. Biswal S, Murthy PN, Sahu J, et al. Vesicles of non-ionic surfactants (niosomes) and drug delivery potential. Int J Pharm Sci Nanotechnol 2008;1:1-8
49. Azmin MN, Florence AT, Handjani-Vila RM, et al. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 1985;37:237-42 (Pubitemid 15149834)
50. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticles systems in cancer therapeutics. Adv Drug Deliv Rev 2008;60:1615-26
51. Mohanraj VJ, Chen Y. Nanoparticles - A Review. Trop J Pharm Res 2006;5:561-73
52. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutyl cyanoacrylate nanoparticles. Int J Pharm 2006;310:213-19 (Pubitemid 43287986)
53. Yang X, Zhang Q, Wang Y, et al. Self-aggregated nanoparticles from methoxy poly(ethylene glycol)-modified chitosan: synthesis; characterization; aggregation and methotrexate release in vitro. Colloids Surf B Biointerfaces 2008;61:125-31
54. Lu W, Wan J, She Z, et al. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release 2007;118:38-53 (Pubitemid 46283096)
55. Utreja S, Khopade AJ, Jain NK. Lipoprotein-mimicking biovectorized systems for methotrexate delivery. Pharm Acta Helv 1999;73:275-9 (Pubitemid 29324992)
56. Mulla JA, Khazi IA, Jamkandi VG. Icbn Poster Session. The preliminary program for SBE's 4th international conference on bioengineering and nanotechnology (ICBN). Available from: http://aiche. confex.com/aiche/ICBN08/ preliminaryprogram/abstract-136778.htm [Last accessed on 23 December 2010]
57. Ruckmani K, Sivakumar M, Ganeshkumar PA. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J Nanosci Nanotechnol 2006;6:2991-5 (Pubitemid 44579973)
58. Kalariya M, Padhi BK, Chougule M, et al. Methotrexate-loaded solid lipid nanoparticles for topical treatment of psoriasis: formulation & clinical implications. Drug Deliv Technol 2002;5:1-13
59. Singka GSL, Samah NA, Zulfakar MH, et al. Enhanced topical delivery and anti-inflammatory activity of methotrexate from an activated nanogel. Eur J Pharm Biopharm 2010;76:275-81
60. Mishra PR, Jain NK. Biotinylated methotrexate loaded erythrocytes for enhanced liver uptake. A study on the rat. Int J Pharm 2002;231:145-53 (Pubitemid 34033674)
61. Trotta M, Pattarino F, Gasco MR. Influence of counter ions on the skin permeation of methotrexate from water-oil microemulsions. Pharm Acta Helv 1996;71:135-40 (Pubitemid 26281323)
62. Paliwal R, Paliwal SR, Mishra N, et al. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. Int J Pharm 2009;380:181-8
63. Kang H, Kim JD, Han SH, et al. Self-aggregates of poly(2-hydroxyethyl aspartamide) copolymers loaded with methotrexate by physical and chemicalentrapments. J Control Release 2002;81:135-44 (Pubitemid 34454855)
64. Dhanikula RS, Hildgen P. Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of methotrexate. Biomaterials 2007;28:3140-52 (Pubitemid 46656188)
65. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005;65:5317-24 (Pubitemid 40827344)
66. Takakura Y, Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit Rev Oncol Hematol 1995;18:207-31
67. Fitzpatrick JJ, Garnett MC. Studies on the mechanism of action of an methotrexate -HSA-MoAb conjugate. Anticancer Drug Des 1995;1:11-24
68. Hudecz F, Clegg JA, Kajtar J, et al. Influence of carrier on biodistribution and in vitro cytotoxicity of methotrexate -branched polypeptide conjugates. Bioconjug Chem 1993;4:25-33
69. Huennekens FM. Development of methotrexate alpha-peptides as prodrugs for activation by enzyme-monoclonal antibody conjugates. Adv Enzyme Regul 1997;37:77-92 (Pubitemid 27371556)
70. Bowman BJ, Ofner CM. Characterization and in vitro methotrexate release from methotrexate/ gelatin conjugates of opposite conjugate bond polarity. Pharm Res 2000;17:1309-5
71. Wu Z, Shah A, Patel N, et al. Development of methotrexate praline prodrug to overcome resistance by MDA-MB-231 cells. Bioorg Med Chem Lett 2010;20:5108-12
72. Affleck K, Embleton MJ. Monoclonal antibody targeting of methotrexate against methotrexate -resistant tumour cell lines. Br J Cancer 1992;65:838-44
73. Ballou B, Jaffe R, Persiani S, et al. Tissue localization of methotrexate -monoclonal- IgM immunoconjugates: anti-SSEA-1 and MOPC 104E in mouse tetracarcinomas and normal tissues. Cancer Immunol Immunother 1992;35:251-6
74. Endo N, Takeda Y, Kishida K, et al. Target-selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody. Cancer Immunol Immunother 1987;25:1-6 (Pubitemid 17117957)
75. Boratynski J, Opolski A, Wietrzyk J, et al. Cytotoxic and antitumor effect of fibrinogen- methotrexate conjugate. Cancer Lett 2000;148:189-95 (Pubitemid 30047107)
76. Calderon MR, Graeser Kratz F, et al. Development of enzymatically cleavable prodrugs derived from dendritic polyglycerol. Bioorg Med Chem Lett 2009;19:3725-8
77. Shen WC, Du X, Feener EP, et al. The intracellular release of methotrexate from a synthetic drug carrier system targeted to fc receptor-bearing cells. J Control Release 1989;10:89-96 (Pubitemid 19253816)
78. Endo N, Kato Y, Takeda Y, et al. In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-mm46 monoclonal antibody. Cancer Res 1987;47:1076-80 (Pubitemid 17027932)
79. Lim CR, Oh KH, Kim KM, et al. The enhancement of liver targetability of [3H] methotrexate -galactosylated serum albumin conjugate in mice. Int J Pharm 1996;32:175-82 (Pubitemid 26158718)
80. Okarvi SM, Jammaz IA. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors. Nucl Med Biol 2010;37:277-88
81. Kosasih A, Bowman BJ, Wigent RJ, et al. Characterization and in vitro release of methotrexate from gelatin/ methotrexate conjugates formed using different preparation variables. Int J Pharm 2000;204:81-9
82. Ofner CM, Pica K, Bowman BJ, et al. Growth inhibition, drug load, and degradation studies of gelatin/ methotrexate conjugates. Int J Pharm 2006;308:90-9 (Pubitemid 43097239)
83. Smal MA, Dong Z, Cheung HTA, et al. Activation and cytotoxicity of 2-a-aminoacyl prodrugs of methotrexate. Cancer Lett 2000;148:189-95
84. Vitols KS, Haag-Zeino B, Baer T, et al. Methotrexate -alpha- phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase a-monoclonal antibody conjugate. Cancer Res 1995;55:478-81
85. Perron MJ, Page M. Activation of methotrexate -phenylalanine by monoclonal antibody carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro. Br J Cancer 1996;73:281-7
86. Pignatello R, Spampinato G, Sorrenti V, et al. Lipophilic methotrexate conjugates with antitumor activity. Eur J Pharm Sci 2000;10:237-45 (Pubitemid 30190099)
87. Li Y, Kwon GS. Micelle-like structures of poly(ethyleneoxide)-block- poly(2- hydroxyethyl aspartamide)- methotrexate conjugates. Colloids Surf B Biointerfaces 1999;16:217-26 (Pubitemid 29486808)
88. Kaasgaarda T, Andresena TL, Jensen SS, et al. Liposomes containing alkylated methotrexate analogues for phospholipase A2 mediated tumor targeted drug delivery. Chem Phys Lipids 2009;157:94-03
89. Santos MA, Enyedy EA, Nuti E, et al. Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem 2007;15:1266-74 (Pubitemid 46038141)
90. Mctavish H, Griffin RJ, Kaoru T, et al. Novel insulin-like growth factormethotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone. Transl Res 2009;153:275-82
91. Subr V, Strohalm J, Hirano T, et al. Poly[N-(2-hydroxypropyl) methacrylamide] conjugates of methotrexate synthesis and in vitro drug release. J Control Release 1997;49:123-32 (Pubitemid 28020265)
92. Fitzpatrick JJ, Garnett MC. Design, synthesis and in vitro testing of methotrexate carrier conjugates linked via oligopeptide spacers. Anticancer Drug Des 1995;10:1-9
93. Senter PD, Springer CJ. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev 2001;53:247-64 (Pubitemid 34024909)
94. Smith GK, Banks S, Blumenkopf TA, et al. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. J Biol Chem 1997;272:15804-16 (Pubitemid 27265558)
95. Pietersz GA, Cunningham Z, McKenzi IFC. Specific in vitro anti-tumour activity of methotrexate monoclonal antibody conjugates prepared using human serum albumin as an intermediary. Immunol Cell Biol 1988;66:43-9 (Pubitemid 18096925)
96. Homma A, Sato H, Okamachi A, et al. Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment. Bioorg Med Chem 2009;17:4647-56
97. Chakraborty P, Bhaduri AM, Das PK. Sugar receptor mediated drug delivery to macrophage in the therapy of experimental visceral leishmaniasis. Biochem Biophys Res Commun 1990;166:404-10 (Pubitemid 20040200)
98. Chakraborty P, Bhaduri AM, Das PK. Neoglycoproteins as carriers for receptor-mediated drug targeting in the treatment of experimental visceral leishmaniasis. J Protozool 1990;37:358-64 (Pubitemid 20353678)
99. Mukhopadhyay A, Chaudhuri G, Arora SK, et al. Receptor mediated drug delivery to macrophages in chemotherapy of leishmaniasis. Science 1989;244:705-7 (Pubitemid 19147682)
100. Chaudhuri G, Mukhopadhyay A, Basu SK. Selective delivery of drug to macrophages through a highly specific receptor: an efficient chemotherapeutic approach against leishmaniasis. Biochem Pharmacol 1989;38:2995-02
101. Roth BJ, Bajorin DF. Advanced bladder cancer: the need to identify new agents in the post-m-vac (methotrexate, vinblastine, doxorubicin and cisplatin). J Urol 1995;153:894-900
102. Chan KKL, Huang Y, Tam KF, et al. Single dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia. Am J Obstet Gynecol 2006;195:1282-6 (Pubitemid 44635361)
103. Lurain JR, Elfstrand EP. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am J Obstet Gynecol 1995;172:574-9
104. Kohne CH, Harstrick A, Schoffski WHP, et al. Modulation of 5Fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study. Eur J Cancer 1997;33:1896-9
105. Uluoglu C, Oguz A, Timlioglu O, et al. Intermediate dose of methotrexate toxicity in non-Hodgkin lymphoma. Gen Pharmacol 1999;32:215-18 (Pubitemid 29127118)
106. Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40:2071-6 (Pubitemid 39165540)
107. Segal R, Yaron M, Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990;20:190-200
108. Furst DE. Proposition: methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs fail. Semin Arthritis Rheum 1990;20:69-75 (Pubitemid 20364838)
109. Zintzaras E, Dahabreh IJ, Giannouli S, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther 2008;30:1939-55
110. Xinqiang S, Fei L, Nan L, et al. Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+ CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomed Pharmacother 2010;64:463-71
111. Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005;11:154-63 (Pubitemid 40082381)
112. Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:388-95 (Pubitemid 44056248)
113. Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009;60:402-11
114. Scully CJ, Anderson CJ, Cannon GW. Long-term methotrexate therapy for rheumatoid arthritis. Semin Arthritis Rheum 1991;20:317-31
115. Stewart KA, Mackenzie AH, Clough JD, et al. Folate supplementation in methotrexate treated rheumatoid arthritis patients. Semin Arthritis Rheum 1991;20:332-8
116. Schnabel A, Gross WL. Low-dose methotrexate in rheumatic diseases, efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994;23:310-27 (Pubitemid 24116664)
117. Furst DE. Should methotrexate be used to treat early rheumatoid arthritis? Semin Arthritis Rheum 1994;23:39-43 (Pubitemid 24189755)
118. Pymar HC, Creinin MD. Alternatives to mifepristone regimens for medical abortion. Am J Obstet Gynecol 2000;183:S54-64 (Pubitemid 30663403)
119. Creinin MD, Krohn MA. Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. Am J Obstet Gynecol 1997;177:1444-9 (Pubitemid 28040241)
120. Creinin MD, Wiebe E, Gold M. Methotrexate and misoprostol for early abortion in adolescent women. J Pediatr Adolesc Gynecol 1999;12:71-7 (Pubitemid 29516338)
121. Creinin MD, Vittinghofft E. Keder Li, et al. Methotrexate and misoprostol for early abortion: a multicenter trial I. Safety and efficacy. Contraception 1996;53:321-2
122. Carbonell JLL, Varela L, Velazco A, et al. Oral methotrexate and vaginal misoprostol for early abortion. Contraception 1998;57:83-8 (Pubitemid 28208477)
123. Ozeren M, Cand B, Aydemir V, et al. Methotrexate and misoprostol used alone or in combination for early abortion. Contraception 1999;59:389-94 (Pubitemid 29430167)
124. Wiebe ER. Abortion induced with methotrexate and misoprostol: a comparison of various protocols. Contraception 1997;55:159-63 (Pubitemid 27180391)
125. Stika CS, Anderson L, Frederiksen MC. Single-dose methotrexate for thetreatment of ectopic pregnancy: Northwestern Memorial Hospital three-year experience. Am J Obstet Gynecol 1996;174:1840-8 (Pubitemid 26247593)
126. Wiebe ER. Tamoxifen compared to methotrexate when used with misoprostol for abortion. Contraception 1999;59:265-70 (Pubitemid 29361483)
127. Uwai Y, Saito H, Inui K. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol 2000;409:31-6